title: The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia.
authors.affiliation: jcortes@mdanderson.org.
authors.forename: Aziz
authors.initials: A
authors.lastname: Nazha
authors.forename: Carlos G
authors.initials: CG
authors.lastname: Romo
authors.forename: Hagop
authors.initials: H
authors.lastname: Kantarjian
authors.forename: Jorge
authors.initials: J
authors.lastname: Cortes
mesh_terms: D001792:Blood Platelets / Q000473:pathology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011724:Pyridazines / Q000494:pharmacology*
chemical_list: D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl
keywords: bleeding; chronic myeloid leukemia; ponatinib